GI & Hepatology News Video Insights

Each month, select summaries featured in the “From the Pages of Clinical Gastroenterology and Hepatology and Gastroenterology” section include accompanying Video Insights — short videos of the studies’ authors discussing their research. You’ll learn the motivation behind the studies and how the results contribute to our overall understanding of digestive disease.

October 2014

Topic 1:

Risk of Upper Gastrointestinal Bleeding From Different Drug Combinations

Description:

Dr. Gwen M.C. Masclee discusses her manuscript “Risk of Upper Gastrointestinal Bleeding From Different Drug Combinations.”

Topic 2:

Risk Stratification of Emergency Department Patients With Crohn's Disease Could Reduce Computed Tomography Use by Nearly Half

Description:

Drs. Shail M. Govani and Peter Higgins discuss their manuscript “Risk Stratification of Emergency Department Patients With Crohn's Disease Could Reduce Computed Tomography Use by Nearly Half.”

Topic 3:

Incidence, Outcomes, and Health Services Burden of Very Early Onset Inflammatory Bowel Disease

Description:

Dr. Eric I. Benchimol discusses his manuscript “Incidence, Outcomes, and Health Services Burden of Very Early Onset Inflammatory Bowel Disease.”

 

September 2014

Topic 1:

Risks of Serious Infection or Lymphoma With Anti–Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic Review

Description:

Dr. Parambir S. Dulai discusses his manuscript “Risks of Serious Infection or Lymphoma With Anti–Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic Review.”

Topic 2:

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

Description:

Dr. Bruce E. Sands discusses his manuscript “Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed.”

Topic 3:

Postoperative Therapy With Infliximab Prevents Long-term Crohn’s Disease Recurrence

Description:

Dr. Miguel Regueiro discusses his manuscript “Postoperative Therapy With Infliximab Prevents Long-term Crohn’s Disease Recurrence.”

August 2014

Topic:

ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection

Description:

Dr. Pietro Andreone discusses his manuscript “ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection.”

April 2014

Topic 1 :

Characteristics of Missed or Interval Colorectal Cancer and Patient Survival: A Population-Based Study

Description:

Dr. N. Jewel Samadder discusses his manuscript “Characteristics of Missed or Interval Colorectal Cancer and Patient Survival: A Population-Based Study.”

Topic 2 :

Long-term Outcomes of Patients With Wilson Disease in a Large Austrian Cohort

Description:

Dr. Sandra Beinhardt discusses her manuscript “Long-term Outcomes of Patients With Wilson Disease in a Large Austrian Cohort.”

February 2014

Topic 1 :

Guidance on Preparing an Investigational New Drug Application for Fecal Microbiota Transplantation Studies

Description:

Dr. Sachin S, Kunde discusses his manuscript “Guidance on Preparing an Investigational New Drug Application for Fecal Microbiota Transplantation Studies.”

Topic 2:

Increased Effectiveness of Early Therapy With Anti--Tumor Necrosis Factor-? vs an Immunomodulator in Children With Crohn's Disease

Description:

Dr. Thomas D. Walters discusses his manuscript “Increased Effectiveness of Early Therapy With Anti--Tumor Necrosis Factor-? vs an Immunomodulator in Children With Crohn's Disease.”

Topic 3:

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection

Description:

Dr. Gregory T. Everson discusses his manuscript “Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection.”

Archives